X
Zogenix slumps after FDA refuses epilepsy drug file
https://pharmaphorum.com/news/zogenix-slumps-after-fda-refuses-epilepsy-drug-file/
Zogenix
Zogenix gains Breakthrough status, but GW Pharma still ahead in Dravet syndrome
The FDA has granted Zogenix a Breakthrough Therapy Designation for its pipeline product, ZX008 for the treatment of seizures associated with Dravet syndrome.